View More Recent Stories

Feb 25, 2022 06:00AM SAB Biotherapeutics Announces Update to the Phase 3 NIH ACTIV-2 Trial Design Evaluating SAB-185 for Treatment of COVID-19
Jan 24, 2022 06:00AM SAB Biotherapeutics Reports Positive Phase 2 Virology Data Demonstrating SAB-185 Met Criteria for Advancement to Phase 3 in NIH ACTIV-2 Trial for Treatment of COVID-19
Jan 5, 2022 07:00AM SAB Biotherapeutics to Present at 2022 H.C. Wainwright BioConnect Virtual Conference
Dec 20, 2021 06:00AM SAB Biotherapeutics Added to NASDAQ Biotechnology Index
Dec 16, 2021 06:01AM SAB Biotherapeutics (SABS) Reports SAB-185 Retains Neutralization Against Omicron SARS-CoV-2 Variant In Vitro
Dec 16, 2021 06:00AM SAB Biotherapeutics Announces SAB-185 Retains Neutralization Against Omicron SARS-CoV-2 Variant In Vitro
Dec 1, 2021 07:01AM SAB Biotherapeutics (SABS) Announces SAB-176 Met its Primary Endpoint in Phase 2a Challenge Study in Adults Infected with Influenza Virus
Dec 1, 2021 07:00AM SAB Biotherapeutics Announces SAB-176 Met its Primary Endpoint in Phase 2a Challenge Study in Adults Infected with Influenza Virus
Nov 22, 2021 07:00AM SAB Biotherapeutics Reports Third Quarter 2021 Financial Results and Provides Company Update
Oct 25, 2021 07:39AM SAB Biotherapeutics Debuts as Publicly Traded Next-Generation Immunotherapy Company
View More Recent Stories